Literature DB >> 1350483

Clinical experience with dual-acting drugs in hypertension.

K H Rahn1.   

Abstract

There are now several antihypertensive agents with dual actions. Among these, labetalol has been studied most extensively. The drug has a place in the chronic treatment of hypertension and in the therapy of hypertensive emergencies. Carvedilol, now available in Germany, has been shown to be effective in different forms of hypertension. Celiprolol binds to beta 1- and beta 2-receptors. This drug also binds to alpha 2-receptors. It is not clear, at present, whether or not this binding property contributes to its antihypertensive effect.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1350483     DOI： 10.1007/bf00207610

Source DB:  PubMed          Journal:  Clin Investig        ISSN： 0941-0198


  18 in total

1.  Alpha and beta adrenergic blockade with orally administered labetalol in hypertension. Studies on blood volume, plasma renin and aldosterone and catecholamine excretion.

Authors:  P Weidmann; R De Chătel; W H Ziegler; J Flammer; F Reubi
Journal:  Am J Cardiol       Date:  1978-03       Impact factor: 2.778

2.  Alpha-adrenoceptor blockade by labetalol during long-term dosing.

Authors:  A Semplicini; A C Pessina; G P Rossi; M Hlede; F Morandin
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

3.  Labetalol in long-term treatment of hypertension.

Authors:  B N Prichard; A J Boakes
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

4.  Pharmacodynamics of intravenous labetalol and follow-up therapy with oral labetalol.

Authors:  N D Vlachakis; R F Maronde; J W Maloy; M Medakovic; N Kassem
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

5.  Blood pressure, body fluid volumes and glomerular filtration rate during treatment with labetalol in essential hypertension.

Authors:  S Rasmussen; P E Nielsen
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

6.  Combined alpha/beta-blockade versus beta 1-selective blockade in essential hypertension in black and white patients.

Authors:  R R Townsend; D J DiPette; R Goodman; D Blumfield; R Cronin; A Gradman; L A Katz; E P McCarthy; G Sopko
Journal:  Clin Pharmacol Ther       Date:  1990-12       Impact factor: 6.875

7.  Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension.

Authors:  G Keusch; P Weidmann; W H Ziegler; R de Châtel; F C Reubi
Journal:  Klin Wochenschr       Date:  1980-01-02

Review 8.  Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.

Authors:  P Lund-Johansen
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 9.  Pharmacology of combined alpha-beta-blockade. I.

Authors:  W J Louis; J J McNeil; O H Drummer
Journal:  Drugs       Date:  1984       Impact factor: 9.546

10.  Labetalol hepatotoxicity.

Authors:  J A Clark; H J Zimmerman; L A Tanner
Journal:  Ann Intern Med       Date:  1990-08-01       Impact factor: 25.391
View more
  1 in total

Review 1.  Pharmacological profile of beta-adrenoceptor blockers with vasodilating properties, especially carvedilol--rationale for clinical use.

Authors:  G Sponer; W Bartsch; K Strein
Journal:  Clin Investig       Date:  1992
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.